The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization
- PMID: 18172018
- DOI: 10.1176/appi.ajp.2007.07010043
The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization
Abstract
Objective: The consensus cognitive battery developed by the National Institute of Mental Health's (NIMH's) Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative includes 10 independently developed tests that are recommended as the standard battery for clinical trials of cognition-enhancing interventions for schizophrenia. To facilitate interpretation of results from the MATRICS Consensus Cognitive Battery using a common scaling across tests, normative data were obtained from a single representative U.S. community sample with the battery administered as a unit.
Method: The MATRICS Consensus Cognitive Battery was administered to 300 individuals from the general community at five sites in differing geographic regions. For each site, recruitment was stratified by age, gender, and education. A scientific survey sampling method was used to help avoid sampling bias. The battery was administered in a standard order to each participant in a single session lasting approximately 60 minutes. Descriptive data were generated, and age, gender, and education effects on performance were examined.
Results: Prominent age and education effects were observed across tests. The results for gender differed by measure, suggesting the need for age and gender corrections in clinical trials. The MATRICS Consensus Cognitive Battery components were co-normed, with allowance for demographic corrections.
Conclusions: Co-norming a battery such as the MATRICS Consensus Cognitive Battery, comprising tests from independent test developers each with their own set of norms, facilitates valid interpretation of test scores and communication of findings across studies. These normative data will aid in estimating the magnitude of change during clinical trials of cognition-enhancing agents and make it possible to derive more directly interpretable composite scores.
Comment in
-
Pharmacological treatment of cognition in schizophrenia: an idea whose method has come.Am J Psychiatry. 2008 Feb;165(2):163-5. doi: 10.1176/appi.ajp.2007.07111810. Am J Psychiatry. 2008. PMID: 18245181 No abstract available.
-
Wayne Fenton, M.D.Am J Psychiatry. 2008 Feb;165(2):177-8. doi: 10.1176/appi.ajp.2007.07121839. Am J Psychiatry. 2008. PMID: 18245186 No abstract available.
-
Interpreting T scores and percentile equivalents using the MATRICS consensus cognitive battery in schizophrenia trials.Am J Psychiatry. 2008 Jul;165(7):914; author reply 914-5. doi: 10.1176/appi.ajp.2008.08030379. Am J Psychiatry. 2008. PMID: 18593789 No abstract available.
Similar articles
-
Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.Am J Psychiatry. 2008 Feb;165(2):221-8. doi: 10.1176/appi.ajp.2007.07010089. Epub 2008 Jan 2. Am J Psychiatry. 2008. PMID: 18172017
-
[Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].Encephale. 2008 Dec;34(6):557-62. doi: 10.1016/j.encep.2007.12.005. Epub 2008 Jul 9. Encephale. 2008. PMID: 19081451 French.
-
The MATRICS consensus cognitive battery (MCCB): co-norming and standardization in Spain.Schizophr Res. 2012 Feb;134(2-3):279-84. doi: 10.1016/j.schres.2011.11.026. Epub 2011 Dec 20. Schizophr Res. 2012. PMID: 22192501
-
Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.Biol Psychiatry. 2004 Sep 1;56(5):301-7. doi: 10.1016/j.biopsych.2004.06.023. Biol Psychiatry. 2004. PMID: 15336511 Review.
-
[Measuring the cognitive deficit associated with schizophrenia: presentation of the MATRICS neuropsychological test battery].Neuropsychopharmacol Hung. 2007 Oct;9(3):143-50. Neuropsychopharmacol Hung. 2007. PMID: 18399033 Review. Hungarian.
Cited by
-
Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment in schizophrenia: results from the multicenter FACE-SZ cohort.Front Pharmacol. 2024 Jun 12;15:1403093. doi: 10.3389/fphar.2024.1403093. eCollection 2024. Front Pharmacol. 2024. PMID: 38933674 Free PMC article.
-
Social Cognition Impairments in 22q11.2DS Individuals With and Without Psychosis: A Comparison Study With a Large Population of Patients With Schizophrenia.Schizophr Bull Open. 2021 Nov 10;3(1):sgab049. doi: 10.1093/schizbullopen/sgab049. eCollection 2022 Jan. Schizophr Bull Open. 2021. PMID: 39144801 Free PMC article.
-
Clozapine Reverses Dysfunction of Glutamatergic Neurons Derived From Clozapine-Responsive Schizophrenia Patients.Front Cell Neurosci. 2022 Feb 23;16:830757. doi: 10.3389/fncel.2022.830757. eCollection 2022. Front Cell Neurosci. 2022. PMID: 35281293 Free PMC article.
-
The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?Schizophr Bull. 2011 Nov;37(6):1209-17. doi: 10.1093/schbul/sbq038. Epub 2010 Apr 21. Schizophr Bull. 2011. PMID: 20410237 Free PMC article.
-
The assessment of neuropsychological functioning in schizophrenia.Dialogues Clin Neurosci. 2010;12(3):383-92. doi: 10.31887/DCNS.2010.12.3/areichenberg. Dialogues Clin Neurosci. 2010. PMID: 20954432 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical